{"schema_version":"secwatch.filing_event.v1","accession":"0001021771-25-000092","form_type":"8-K","ticker":"BRTX","cik":"0001505497","company_name":"BioRestorative Therapies, Inc.","filed_at":"2025-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.520442+00:00","generated_at":"2026-05-19T08:04:35.282735+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"BioRestorative presents Phase 2 data for BRTX-100: >50% improvement in pain/function in >70% of subjects","bullets":["Preliminary blinded data from 36 subjects in Phase 2 trial of BRTX-100 for chronic lumbar disc disease presented at ISSCR 2025.","Over 74% of subjects showed >50% improvement in function (ODI) by week 52; over 72% had >50% pain reduction (VAS).","No serious adverse events or dose-limiting toxicities reported between 26 and 104 weeks at target dose of 40 million cells.","Number of evaluated subjects increased from 15 to 36 since last update; FDA requires >30% improvement thresholds.","CEO Lance Alstodt expressed confidence BRTX-100 can meet or exceed FDA thresholds for function and pain."],"urls":{"canonical":"https://secwatch.observer/filing/0001021771-25-000092","json":"https://secwatch.observer/filing/0001021771-25-000092.json","markdown":"https://secwatch.observer/filing/0001021771-25-000092.md","text":"https://secwatch.observer/filing/0001021771-25-000092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1505497/000102177125000092/0001021771-25-000092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1505497/000102177125000092/brt8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T08:04:35.282735+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}